M’s Science Corporation Initiated European
Phase 2 Study in Stroke Recovery
KOBE, Japan (Business Wire EON/PRWEB ) January 30, 2008 --
M’s Science Corporation (MSC), a clinical
stage discovery and development company announced today that it
initiated a Phase 2 study in Europe with its lead product SA4503 for
treatment of stroke. Earlier this year, MSC announced the initiation of
a Phase 2 trial with SA4503 for the treatment of major depression.
This latest Phase 2 trial is an international, multi-center,
double-blind and placebo-controlled study of SA4503 in patients with
stroke with a planned enrollment of approximately 60 patients. The
primary objective of the study is to evaluate safety of SA4503 in this
patient population.
SA4503 is a potent and selective agonist of the sigma-1 receptor.
Activation of this receptor is associated with enhancement of recovery
in experimental models of stroke. SA4503 induces neuroregeneration and
facilitates the recovery of damaged tissues from stress or
ischemia-induced insults. This novel mechanism of action allows for a
large time-window of treatment initiation in patients up to 60 hours
after occurrence of stroke. In contrast, thrombolytic treatment must be
applied within 3 hours after stroke, which limits the application of
this therapy to less than 10% of all stroke patients. Therefore, SA4503
may address a significant medical need for effective stroke therapy with
an expanded time-window of treatment initiation. Consequently, a larger
proportion of stroke patients may potentially benefit from a therapy
with SA4503.
“The role of the sigma-1 receptor in enhancing
recovery from stroke was discovered by a functional genomics approach.
SA4503 is among the first therapies acting on the central nervous system
that resulted from the application of this innovative technology,”
commented Dr. Roman Urfer, Senior Vice President International
Development.
“Stroke poses significant therapeutic
challenges. SA4503 with its unique and unexploited mechanism has the
potential to address the limitations of today’s
stroke therapies,” said Dr. Shiro Mita,
Chairman and CEO.
“This trial marks an important milestone in
the development of SA4503. Our two on-going Phase 2 trials document our
focused clinical development with this innovative compound. Moreover,
our lead in the sigma-1 receptor field allows us to aggressively pursue
this novel mechanism of action in additional indications,”
commented Mr. Akihiko Shimauchi, President and COO.
About M’s Science Corporation
M’s Science (MSC) is a privately held
biopharmaceutical company dedicated to the discovery and development of
treatments of central nervous system (CNS) disorders and cancer. MSC
currently develops two clinical stage products, SA4503 and HF10.
SA4503 is a potent and selective agonist of the sigma-1 receptor. MSC
will initially focus its clinical development of SA4503 on the treatment
of major depression and on the enhancement of recovery from stroke.
HF10 is a natural isolate of an attenuated herpes simplex virus and
possesses strong tumor killing ability. MSC initially develops HF10 for
the treatment of head & neck cancer and intends to expand its
application to other cancers.
See the original story at: http://eon.businesswire.com/releases/sa4503/stroke/prweb665964.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1JbnNlLUxvdmUtQ291cC1aZXRhLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
